Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab

References

• FrohmanEMRackeMKRaineCSMultiple sclerosis – the plaque and its pathogenesisN Engl J Med200635494295516510748
   PubMed Web of Science ®Google Scholar
• BrickshawanaAHinsonSRRomeroMFInvestigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative studyLancet Neurol20141379580625008548
   PubMed Web of Science ®Google Scholar
• ConfavreuxCAimardGDevicMCourse and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patientsBrain19801032813007397479
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyGilenya Summary of Product Characteristics2011 Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdfAccessed August 1, 2015
   Google Scholar
• FazekasFBajenaruOBergerTHow does fingolimod (gilenya((R))) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?Front Neurol201341023641231
   PubMed Web of Science ®Google Scholar
• DevonshireVHavrdovaERadueEWFREEDOMS study groupRelapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS studyLancet Neurol20121142042822494956
   PubMed Web of Science ®Google Scholar
• HirstCLPaceAPickersgillTPCampath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosisJ Neurol200825523123818283404
   PubMed Web of Science ®Google Scholar
• Cobo-CalvoÁBauLMatasEEffectiveness of natalizumab in patients with highly active relapsing remitting multiple sclerosisEur Neurol20157322022925792347
   PubMed Web of Science ®Google Scholar
• OstbergAPittasFTaylorBUse of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis statusIntern Med J20053538238715958106
   PubMed Web of Science ®Google Scholar
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study GroupLancet1998352149815049820297
   PubMed Web of Science ®Google Scholar
• IFNB Multiple Sclerosis Study GroupInterferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study GroupNeurology19934346556618469318
   PubMed Web of Science ®Google Scholar
• JacobsLDCookfairDLRudickRAIntramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)Ann Neurol1996392852948602746
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis GroupInterferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trialNeurology1995457127712857617182
   PubMed Web of Science ®Google Scholar
• DubeyDKieseierBCHartungHPHemmerBMiller-LittleWAStuveOClinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidatesExpert Rev Clin Immunol2015119310825495182
   PubMed Web of Science ®Google Scholar
• HaleGThe CD52 antigen and development of the CAMPATH antibodiesCytotherapy2001313714312171721
   PubMed Web of Science ®Google Scholar
• ElsnerJHochstetterRSpiekermannKKappASurface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophilsBlood199688468446938977262
   PubMed Web of Science ®Google Scholar
• HaleGRyePDWarfordALauderIBrito-BabapulleAThe glycosylphosphatidylinositol-anchored lymphocyte antigen CDw52 is associated with the epididymal maturation of human spermatozoaJ Reprod Immunol1993231892057685389
   PubMed Web of Science ®Google Scholar
• HaleGZhangMJBunjesDImproving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejectionBlood199892458145909845524
   PubMed Web of Science ®Google Scholar
• OakhillAPamphilonDHPotterMNUnrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remissionBr J Haematol1996945745788790160
   PubMed Web of Science ®Google Scholar
• PhillipsJDrummAHarrisonPManufacture and quality control of CAMPATH-1 antibodies for clinical trialsCytotherapy2001323324212171730
   PubMed Web of Science ®Google Scholar
• MengeTStuveOKieseierBCHartungHPAlemtuzumab: the advantages and challenges of a novel therapy in MSNeurology201483879724920854
   PubMed Web of Science ®Google Scholar
• MoneAPCheneyCBanksALAlemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanismLeukemia20062027227916341049
   PubMed Web of Science ®Google Scholar
• RiechmannLClarkMWaldmannHWinterGReshaping human antibodies for therapyNature19883323233273127726
   PubMed Web of Science ®Google Scholar
• RowanWTiteJTopleyPBrettSJCross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cellsImmunology1998954274369824507
   PubMed Web of Science ®Google Scholar
• NuckelHFreyUHRothADuhrsenUSiffertWAlemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicityEur J Pharmacol200551421722415910809
   PubMed Web of Science ®Google Scholar
• JonesDTGaneshaguruKVirchisAECaspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiationBlood2001982800280711675354
   PubMed Web of Science ®Google Scholar
• JonesJLAndersonJMPhuahCLImprovement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunityBrain20101332232224720659956
   PubMed Web of Science ®Google Scholar
• CossburnMDHardingKIngramGClinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosisNeurology201380556123243077
   PubMed Web of Science ®Google Scholar
• HavrdovaEHorakovaDKovarovaIAlemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for useTher Adv Neurol Disord20158314525584072
   PubMed Web of Science ®Google Scholar
• WillisMDRobertsonNPAlemtuzumab for the treatment of multiple sclerosisTher Clin Risk Manag20151152553425848299
   PubMed Web of Science ®Google Scholar
• ElterTMolnarIKuhlmannJHallekMWendtnerCPharmacokinetics of alemtuzumab and the relevance in clinical practiceLeuk Lymphoma2008492256226219052972
   PubMed Web of Science ®Google Scholar
• CAMMS223 Trial InvestigatorsColesAJCompstonDASelmajKWAlemtuzumab vs. interferon beta-1a in early multiple sclerosisN Engl J Med20083591786180118946064
   PubMed Web of Science ®Google Scholar
• CohenJAColesAJArnoldDLCARE-MS I investigatorsAlemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialLancet20123801819182823122652
   PubMed Web of Science ®Google Scholar
• ColesAJTwymanCLArnoldDLCARE-MS II investigatorsAlemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialLancet20123801829183923122650
   PubMed Web of Science ®Google Scholar
• ColesAJFoxEVladicAAlemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trialNeurology2012781069107822442431
   PubMed Web of Science ®Google Scholar
• TuohyOCostelloeLHill-CawthorneGAlemtuzumab treatment of multiple sclerosis: long-term safety and efficacyJ Neurol Neurosurg Psychiatry20158620821524849515
   PubMed Web of Science ®Google Scholar
• PerumalJSFooFCookPKhanOSubcutaneous administration of alemtuzumab in patients with highly active multiple sclerosisMult Scler2012181197119922252465
   PubMed Web of Science ®Google Scholar
• LePEDeburghgraeveVLesterMACardietILerayEEdanGAlemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational studyJ Neurol20152621024103425701008
   PubMed Web of Science ®Google Scholar
• HutchinsonMKapposLCalabresiPAAFFIRM and SENTINEL InvestigatorsThe efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINELJ Neurol200925640541519308305
   PubMed Web of Science ®Google Scholar
• DerfussTBergvallNKSfikasNTomicDLEfficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosisCurr Med Res Opin Epub2015824
   Web of Science ®Google Scholar
• GiovannoniGRadueEWHavrdovaEEffect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosisJ Neurol201426131632324375015
   PubMed Web of Science ®Google Scholar
• CorrealeJRushCAmengualAGoicocheaMTMitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-betaJ Neuroimmunol200516217318315833373
   PubMed Web of Science ®Google Scholar
• FoxEJManagement of worsening multiple sclerosis with mitoxantrone: a reviewClin Ther20062846147416750460
   PubMed Web of Science ®Google Scholar
• SaccardiRMancardiGLSolariAAutologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of lifeBlood20051052601260715546956
   PubMed Web of Science ®Google Scholar
• MancardiGLSormaniMPGualandiFASTIMS Haema-to-Neurological Collaborative GroupOn behalf of the Autoimmune Disease Working Party (ADWP) of the European Group for Blood and Marrow Transplantation (EBMT)ASTIMS Haemato-Neurological Collaborative Group On behalf of the Autoimmune Disease Working Party ADWP of the European Group for Blood and Marrow Transplantation EBMTAutologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trialNeurology20158498198825672923
   PubMed Web of Science ®Google Scholar
• DaikelerTTichelliAPasswegJComplications of autologous hematopoietic stem cell transplantation for patients with autoimmune diseasesPediatr Res20127143944422430379
   PubMed Web of Science ®Google Scholar
• HaleGBrightSChumbleyGRemoval of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complementBlood1983628738826349718
   PubMed Web of Science ®Google Scholar
• JacobsPWoodLFullardLWaldmannHHaleGT cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host diseaseBone Marrow Transplant1994137637697920312
   PubMed Web of Science ®Google Scholar
• JonesJLPhuahCLCoxALIL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)J Clin Invest20091192052206119546505
   PubMed Web of Science ®Google Scholar
• CukerAColesAJSullivanHA distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosisBlood20111186299630521960587
   PubMed Web of Science ®Google Scholar
• MeyerDColesAOyuelaPPurvisAMargolinDHCase report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing-remitting multiple sclerosisMult Scler Relat Disord20132606325877456
   PubMed Web of Science ®Google Scholar
• LEMTRADA REMS program overview Available from https://www.lemtradarems.com/Docs/Pdf/LEMTRADA_REMS_Program_Overview.pdfAccessed August 1, 2015
   Google Scholar
• FDA Approves Lemtrada™ (alemtuzumab) for Relapsing MS – UPDATE2014 Available from http://www.nationalmssociety.org/About-the-Society/News/FDA-Approves-Lemtrada%E2%84%A2-(alemtuzumab)-for-RelapsingAccessed August 1, 2015
   Google Scholar
• Disease Modification2015 Available from http://www.nationalmssociety.org/For-Professionals/Clinical-Care/Managing-MS/Disease-Modification#section-1Accessed August 1, 2015
   Google Scholar
• Genzyme Details Market Potential of Alemtuzumab for MS2014 Available from http://www.worldpharmanews.com/genzyme/1529-genzyme-details-market-potential-of-alemtuzumab-for-msAccessed August 1, 2015
   Google Scholar